CO2019015100A2 - Anticuerpos biespecíficos inhibidores de punto de control - Google Patents

Anticuerpos biespecíficos inhibidores de punto de control

Info

Publication number
CO2019015100A2
CO2019015100A2 CONC2019/0015100A CO2019015100A CO2019015100A2 CO 2019015100 A2 CO2019015100 A2 CO 2019015100A2 CO 2019015100 A CO2019015100 A CO 2019015100A CO 2019015100 A2 CO2019015100 A2 CO 2019015100A2
Authority
CO
Colombia
Prior art keywords
checkpoint inhibitor
inhibitor antibodies
bispecific checkpoint
antibodies
bispecific
Prior art date
Application number
CONC2019/0015100A
Other languages
English (en)
Inventor
Yiwen Li
Dale Lincoln Ludwig
Yang Shen
Michael Dewain Kalos
Gregory D Plowman
Igor Edmondo Paolo D'angelo
Original Assignee
Lilly Co Eli
Zymeworks Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Zymeworks Inc filed Critical Lilly Co Eli
Publication of CO2019015100A2 publication Critical patent/CO2019015100A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a anticuerpos que son heterodiméricos y se unen a PD-L1 humana y PD-1 humana, y pueden ser útiles para tratar cáncer solos en combinación con quimioterapia y otros productos terapéuticos contra el cáncer.
CONC2019/0015100A 2017-07-10 2019-12-30 Anticuerpos biespecíficos inhibidores de punto de control CO2019015100A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762530436P 2017-07-10 2017-07-10
PCT/US2018/041205 WO2019014091A1 (en) 2017-07-10 2018-07-09 BISPECIFIC ANTIBODIES AS INHIBITORS OF CONTROL POINTS

Publications (1)

Publication Number Publication Date
CO2019015100A2 true CO2019015100A2 (es) 2020-04-24

Family

ID=63013165

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0015100A CO2019015100A2 (es) 2017-07-10 2019-12-30 Anticuerpos biespecíficos inhibidores de punto de control

Country Status (26)

Country Link
US (1) US11203640B2 (es)
EP (1) EP3652216A1 (es)
JP (1) JP6953612B2 (es)
KR (1) KR102309950B1 (es)
CN (1) CN110914306B (es)
AR (1) AR112603A1 (es)
AU (1) AU2018301326B2 (es)
BR (1) BR112020000162A2 (es)
CA (1) CA3069254C (es)
CL (1) CL2020000053A1 (es)
CO (1) CO2019015100A2 (es)
CR (1) CR20190576A (es)
EA (1) EA201992757A1 (es)
IL (1) IL271347B2 (es)
JO (1) JOP20200003B1 (es)
MA (1) MA49563A (es)
MX (1) MX2020000242A (es)
MY (1) MY195071A (es)
NZ (1) NZ760683A (es)
PE (1) PE20200297A1 (es)
PH (1) PH12020500075A1 (es)
SG (1) SG11201911817VA (es)
TW (1) TWI714864B (es)
UA (1) UA126032C2 (es)
WO (1) WO2019014091A1 (es)
ZA (1) ZA201908549B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019003563A (es) 2016-09-29 2019-08-12 Beijing Hanmi Pharmaceutical Co Ltd Construcciones de inmunoglobulina heterodimericas y metodos de preparacion de las mismas.
TN2019000161A1 (en) 2016-11-18 2020-10-05 Beijing Hanmi Pharmaceutical Co Ltd Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody of heterodimeric form and preparation thereof
MX2019011748A (es) 2017-04-01 2020-01-23 Beijing hanmi pharm co ltd Anticuerpo biespecífico heterodimérico tipo estructura de anticuerpo natural anti-pd-l1/anti-pd-1 y preparación del mismo.
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
US11939381B2 (en) * 2018-07-19 2024-03-26 Eli Lilly And Company Bispecific antibodies targeting immune checkpoints
TWI760751B (zh) * 2019-05-29 2022-04-11 美商美國禮來大藥廠 Tigit及pd-1/tigit-結合分子
US11083705B2 (en) * 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
WO2021143767A1 (zh) * 2020-01-15 2021-07-22 信达生物制药(苏州)有限公司 结合pd-1和pd-l1的双特异性抗体的制剂及其用途
WO2021213523A1 (zh) * 2020-04-24 2021-10-28 信达生物制药(苏州)有限公司 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途
WO2021226984A1 (zh) * 2020-05-15 2021-11-18 三生国健药业（上海）股份有限公司 一种抗pd-1和pd-l1的四价双特异性抗体
JP2023116826A (ja) * 2020-05-20 2023-08-23 中外製薬株式会社 抗原結合分子
CN113754773A (zh) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗pd1×pdl1的双特异性抗体
US11865082B2 (en) 2020-09-09 2024-01-09 Hoffmann-La Roche Inc. Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
CN114601924A (zh) * 2020-12-09 2022-06-10 信达生物制药(苏州)有限公司 抗pd-1抗体或其抗原结合片段治疗鳞状非小细胞肺癌的方法
WO2023020315A1 (zh) * 2021-08-19 2023-02-23 南京吉盛澳玛生物医药有限公司 靶向pd-l1/pd-1的抗体及其应用
CN118103067A (zh) * 2021-09-14 2024-05-28 信达生物制药(苏州)有限公司 抗pd-1抗体和化疗药的药物组合及其使用方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
EP2504028A4 (en) * 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
PT2519543T (pt) 2009-12-29 2016-10-07 Emergent Product Dev Seattle Proteínas de ligação de heterodímero e suas utilizações
EP2552957A4 (en) 2010-03-29 2013-11-20 Zymeworks Inc ANTIBODIES HAVING ENHANCED OR DELETED EFFECTIVE FUNCTION
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CA2811323C (en) 2010-09-24 2019-01-15 Zymeworks Inc. System for molecular packing calculations
WO2012040833A1 (en) 2010-09-30 2012-04-05 Zymeworks Inc. Simplifying residue relationships in protein design
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
CN103732628B (zh) 2011-03-03 2017-06-23 酵活有限公司 多价杂多聚体骨架设计和构建体
PT2773671T (pt) 2011-11-04 2021-12-14 Zymeworks Inc Geração de anticorpo heterodimérico estável com mutações no domínio fc
EP2794905B1 (en) 2011-12-20 2020-04-01 MedImmune, LLC Modified polypeptides for bispecific antibody scaffolds
ES2743399T3 (es) 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
AU2013258834B2 (en) 2012-05-10 2017-09-07 Zymeworks Bc Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
EP2847224A4 (en) 2012-05-10 2016-04-27 Zymeworks Inc SINGLE ARM MONOVALENT ANTIBODY CONSTRUCTS AND USES THEREOF
KR20150036606A (ko) 2012-07-13 2015-04-07 자임워크스 인코포레이티드 항-cd3 구조체를 포함하는 이중특이적 비대칭 이형이합체
JP6498601B2 (ja) 2012-07-13 2019-04-10 ザイムワークス，インコーポレイテッド 多価ヘテロ多量体足場設計および構築物
US20140072581A1 (en) 2012-07-23 2014-03-13 Zymeworks Inc. Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains
JP6581505B2 (ja) 2012-10-03 2019-09-25 ザイムワークス，インコーポレイテッド 重鎖および軽鎖ポリペプチドの対を定量化する方法
EP2914634B1 (en) 2012-11-02 2017-12-06 Zymeworks Inc. Crystal structures of heterodimeric fc domains
RU2720472C2 (ru) 2012-11-28 2020-04-30 Займворкс Инк. Сконструированные пары тяжелая-легкая цепи иммуноглобулина и их применение
CA2936785A1 (en) 2014-01-15 2015-07-23 Zymeworks Inc. Bi-specific cd3 and cd19 antigen-binding constructs
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
AU2015265457B2 (en) 2014-05-28 2021-02-18 Zymeworks Bc Inc. Modified antigen binding polypeptide constructs and uses thereof
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
AU2016300208B2 (en) 2015-07-29 2019-08-08 Novartis Ag Combined use of anti PD-1 and anti M-CSF antibodies in the treatment of cancer
WO2017024465A1 (en) * 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
AR105654A1 (es) * 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
WO2017087547A1 (en) 2015-11-17 2017-05-26 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof

Also Published As

Publication number Publication date
IL271347B2 (en) 2024-04-01
JP2020527136A (ja) 2020-09-03
CN110914306A (zh) 2020-03-24
AU2018301326A1 (en) 2019-12-19
KR102309950B1 (ko) 2021-10-08
IL271347B1 (en) 2023-12-01
AU2018301326B2 (en) 2021-05-13
BR112020000162A2 (pt) 2020-07-14
EA201992757A1 (ru) 2020-04-27
TW201920263A (zh) 2019-06-01
WO2019014091A1 (en) 2019-01-17
US11203640B2 (en) 2021-12-21
PE20200297A1 (es) 2020-02-06
CA3069254A1 (en) 2019-01-17
MX2020000242A (es) 2020-08-10
AR112603A1 (es) 2019-11-20
CN110914306B (zh) 2023-06-02
CR20190576A (es) 2020-03-03
MY195071A (en) 2023-01-08
US20190010232A1 (en) 2019-01-10
TWI714864B (zh) 2021-01-01
PH12020500075A1 (en) 2020-11-09
MA49563A (fr) 2020-05-20
JOP20200003A1 (ar) 2020-01-07
JOP20200003B1 (ar) 2023-03-28
UA126032C2 (uk) 2022-08-03
SG11201911817VA (en) 2020-01-30
ZA201908549B (en) 2021-08-25
CL2020000053A1 (es) 2020-10-30
KR20200021982A (ko) 2020-03-02
IL271347A (en) 2020-01-30
JP6953612B2 (ja) 2021-10-27
EP3652216A1 (en) 2020-05-20
NZ760683A (en) 2023-02-24
CA3069254C (en) 2023-09-12

Similar Documents

Publication Publication Date Title
CO2019015100A2 (es) Anticuerpos biespecíficos inhibidores de punto de control
DOP2018000045A (es) Anticuerpos pd-l1
AR105489A1 (es) Anticuerpos pd-1
CO2017010618A2 (es) Anticuerpos contra icos
ECSP17081420A (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales
CO2018001485A2 (es) Diacuerpos monovalentes biespecificos que son capaces de unirse a b7 - h3 y cd3
CO2019014414A2 (es) Moléculas de anticuerpo que se unen a cd73 y usos de las mismas
ECSP17040521A (es) Anticuerpos heterodiméricos que se unen a CD3 y a antígenos tumorales
AR107442A1 (es) Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer
MY195110A (en) Antibodies to PD-1 and uses Thereof
CY1122721T1 (el) Αντισωματα που δεσμευουν αχl
CL2016001723A1 (es) Molécula de anticuerpo que se une al receptor de muerte programada 1 (pd-1) y usos.
CL2016002460A1 (es) Anticuerpos biespecíficos que se unen a cd38 y cd3
BR112018012929A2 (pt) anticorpos anti-cd20/anti-cd3 biespecíficos para tratar leucemia linfoblástica aguda
CL2019002802A1 (es) Anticuerpos biespecíficos anti-pd-l1-anti-tim-3.
AR088171A1 (es) Anticuerpos anti-erbb3 y usos de los mismos
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
CL2018001788A1 (es) Composiciones y métodos para evaluar el riesgo de ocurrencia de cáncer.